Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Bioadaptives (BDPT) EBT Margin (2019 - 2025)

Bioadaptives' EBT Margin history spans 7 years, with the latest figure at 8193.05% for Q3 2025.

  • For Q3 2025, EBT Margin changed N/A year-over-year to 8193.05%; the TTM value through Sep 2025 reached 15237.08%, down 1405969.0%, while the annual FY2024 figure was 5478.48%, 452632.0% down from the prior year.
  • EBT Margin for Q3 2025 was 8193.05% at Bioadaptives, down from 4905.68% in the prior quarter.
  • Across five years, EBT Margin topped out at 265.17% in Q4 2023 and bottomed at 16436.59% in Q2 2024.
  • The 5-year median for EBT Margin is 3918.2% (2022), against an average of 4834.48%.
  • The largest annual shift saw EBT Margin crashed -1181060bps in 2024 before it soared 1153091bps in 2025.
  • A 5-year view of EBT Margin shows it stood at 2326.72% in 2021, then fell by -26bps to 2933.01% in 2022, then soared by 109bps to 265.17% in 2023, then tumbled by -6298bps to 16436.59% in 2024, then soared by 50bps to 8193.05% in 2025.
  • Per Business Quant, the three most recent readings for BDPT's EBT Margin are 8193.05% (Q3 2025), 4905.68% (Q2 2025), and 16436.59% (Q2 2024).